Single‐Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild‐Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. (7th October 2015)

• Record Type: Journal Article
• Authors: Pietrantonio, Filippo; Cremolini, Chiara; Aprile, Giuseppe; Lonardi, Sara; Orlandi, Armando; Mennitto, Alessia; Berenato, Rosa; Antoniotti, Carlotta; Casagrande, Mariaelena; Marsico, Valentina; Marmorino, Federica; Cardellino, Giovanni Gerardo; Bergamo, Francesca; Tomasello, Gianluca; Formica, Vincenzo; Longarini, Raffaella; Giommoni, Elisa; Caporale, Marta; Di Bartolomeo, Maria; Loupakis, Fotios; de Braud, Filippo
• Is Part Of: Oncologist. Volume 20:Number 11(2015)
• Page Start: 1261
• Page End: 1265
• Publication Date: 2015-10-07
• Subjects: Elderly -- Frail -- Metastatic colorectal cancer -- Panitumumab; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2015-0171
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : Background: No prospective trials have specifically addressed the efficacy and safety of panitumumab in elderly patients with metastatic colorectal cancer (CRC). We aimed at assessing the efficacy and safety of single agent panitumumab in "frail" elderly patients diagnosed with metastatic RAS and BRAF wild‐type CRC. Materials and Methods: Forty elderly patients (aged ≥75 years) with metastatic RAS‐BRAF wild‐type CRC received off‐label prescriptions of single‐agent panitumumab at seven Italian institutions. Treatment was administered as first line in patients with absolute contraindication to any chemotherapy or as second‐line treatment after failure of a fluoropyrimidine‐based treatment, in the presence of contraindication to irinotecan. The outcome measures included objective response rate (ORR), as well as progression‐free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. Results: The median PFS and OS were 6.4 months (95% confidence interval [CI]: 4.9–8 months) and 14.3 months (95% CI: 10.9–17.7 months), respectively. ORR was 32.5%, and DCR was 72.5%. Dose reductions related to adverse events (AEs) were reported in 9 (23%) patients, but no permanent treatment discontinuation caused by was reported. The most frequent grade 3 AE was skin rash, with an incidence of 20%. Conclusion: Panitumumab is effective and well‐tolerated in frail elderly patients with RAS‐BRAF wild‐type metastatic CRC and deemed unfit for chemotherapy. A randomized study is needed to confirm these data. Implications for Practice: Treatment of elderly patients with metastatic colorectal cancer represents a difficult challenge in clinical practice. A significant proportion of frail elderly patients do not receive treatment, reflecting ongoing uncertainty of clinical benefit and toxicity of chemotherapy. Unfit condition in this cohort of patients further limits antineoplastic prescription and consequently patient survival. RAS and BRAF wild‐type status could help select an elderly and unfit population that could benefit from anti‐epidermal growth factor receptor single agent therapy. In the present study, single‐agent off‐label panitumumab was effective and well‐tolerated as first‐line treatment in frail elderly patients deemed unfit for chemotherapy for metastatic RAS and BRAF wild‐type colorectal cancer. Abstract : Unfit condition in frail elderly patients limits antineoplastic prescription and consequently patient survival. RAS and BRAF wild‐type status could help select an elderly and unfit population that could benefit from anti‐epidermal growth factor receptor single agent therapy. The results of this study show that single‐agent off‐label panitumumab was effective and well‐tolerated as first‐line treatment in frail elderly patients deemed unfit for chemotherapy for metastatic RAS and BRAF wild‐type colorectal cancer.